TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5

被引：0
|
作者：
Prada, M. [1 ]
Berard, I [2 ]
Walzer, S. [3 ]
Darba, J. [4 ]
Greenwood, B. [5 ]
机构：
[1] Intexo, Rome, Italy
[2] NEXTEP, Paris, France
[3] MArS Market Access & Pricing Strategy GmbH, Weil Am Rhein, Germany
[4] Univ Barcelona, Barcelona, Spain
[5] Decideum, London W8 7JB, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.1761
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY119
引用
收藏
页码：S264 / S264
页数：1
相关论文
共 50 条
  • [31] ELIGIBILITY OF ORPHAN DRUGS FOR PREFERENTIAL REIMBURSEMENT IN EGYPT
    Fasseeh, A. N.
    Elezbawy, B.
    Korra, N.
    Roushdy, M.
    Seyam, A.
    Hayek, N.
    Rahman, Abdel N.
    Abdelhamid, S.
    Fasseeh, N.
    Saad, A. S.
    Elagamy, A.
    Mahmoud, A.
    Sedrak, A. S.
    Elshazly, K.
    Eldebeiky, M.
    Talaat, M.
    Maher, N.
    Abdelaziz, R.
    Refaat, R.
    Akeel, S.
    Adel, R.
    Khalil, S.
    Abaza, S.
    Kalo, Z.
    VALUE IN HEALTH, 2022, 25 (12) : S265 - S265
  • [32] TIME TRENDS IN SEQUENCE OF DRUG LAUNCH ACROSS EU5
    Gubbels, L.
    Dekkers, R.
    Nijhuis, T.
    VALUE IN HEALTH, 2016, 19 (07) : A451 - A451
  • [33] PRICE-DOSE RELATIONSHIP: THE CASE OF ORAL ONCOLOGY DRUGS IN EU5
    Czira, A.
    Pacheco, L.
    Teale, C. W.
    VALUE IN HEALTH, 2017, 20 (09) : A430 - A430
  • [34] Orphan drugs EU regulations
    Mariz, Segundo
    Llinares, Jordi
    Westermark, Kerstin
    BMJ-BRITISH MEDICAL JOURNAL, 2011, 342
  • [35] EU POLICY ON ORPHAN DRUGS
    LEWIS, S
    LANCET, 1995, 345 (8963): : 1500 - 1500
  • [36] AN ANALYSIS OF PRICE AND ACCESS TIMELINE OF ONCOLOGY DRUGS ACROSS EU5 COUNTRIES
    Wang, X.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [37] Orphan Drug Pricing and Reimbursement Policies Lacking in EU
    不详
    PHARMACEUTICAL MEDICINE, 2018, 32 (04) : 297 - 298
  • [38] SINK OR SWIM: HOW CAN SLE BIOLOGICS SUCCESSFULLY ACHIEVE OPTIMAL REIMBURSEMENT AND UPTAKE IN THE EU5?
    Privolnev, Y.
    Albacker, C.
    Nasa, M.
    VALUE IN HEALTH, 2019, 22 : S51 - S52
  • [39] HOW CAN PHARMA INDUSTRY PREPARE ITSELF FOR THE CHANGING PRICING AND REIMBURSEMENT LANDSCAPE OF ORPHAN DRUGS IN EU?
    Mukku, S.
    Pang, F.
    Mcconkey, D.
    VALUE IN HEALTH, 2011, 14 (07) : A357 - A357
  • [40] Pricing and reimbursement of orphan drugs: the need for more transparency
    Steven Simoens
    Orphanet Journal of Rare Diseases, 6
12345